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Avoidable mortality from giving tranexamic acid
to bleeding trauma patients: an estimation based
on WHO mortality data, a systematic literature
review and data from the CRASH-2 trial
Katharine Ker*, Junko Kiriya, Pablo Perel, Phil Edwards, Haleema Shakur and Ian Roberts
Abstract
Background: The CRASH-2 trial showed that early administration of tranexamic acid (TXA) safely reduces mortality
in bleeding in trauma patients. Based on data from the CRASH-2 trial, global mortality data and a systematic
literature review, we estimated the number of premature deaths that might be averted every year worldwide
through the use of TXA.
Methods: We used CRASH-2 trial data to examine the effect of TXA on death due to bleeding by geographical
region. We used WHO mortality data (2008) and data from a systematic review of the literature to estimate the
annual number of in-hospital trauma deaths due to bleeding. We then used the relative risk estimates from the
CRASH-2 trial to estimate the number of premature deaths that could be averted if all hospitalised bleeding
trauma patients received TXA within one hour of injury, and within three hours of injury. Sensitivity analyses were
used to explore the effect of uncertainty in the parameter estimates and the assumptions made in the model.
Results: There is no evidence that the effect of TXA on death due to bleeding varies by geographical region
(heterogeneity p = 0.70). Based on WHO data and our systematic literature review, we estimate that each year
worldwide there are approximately 400,000 in-hospital trauma deaths due to bleeding. If patients received TXA
within one hour of injury then approximately 128,000 (uncertainty range [UR] ≈ 72,000 to 172,000) deaths might
be averted. If patients received TXA within three hours of injury then approximately 112,000 (UR ≈ 68,000 to
148,000) deaths might be averted. Country specific estimates show that the largest numbers of deaths averted
would be in India and China.
Conclusions: The use of TXA in the treatment of traumatic bleeding has the potential to prevent many premature
deaths every year. A large proportion of the potential health gains are in low and middle income countries.
Background
Trauma is a leading cause of death and disability. Each
year, worldwide, an estimated 5.8 million people die as a
result of trauma [1], many after reaching hospital.
Among trauma patients who survive to reach hospital,
bleeding is a common cause of death, accounting for
around 40% of in-hospital trauma deaths [2].
The CRASH-2 trial was an international randomised
controlled trial of the early administration of tranexamic
acid (TXA) to bleeding trauma patients. The trial
recruited 20,211 patients from 274 hospitals in 40 coun-
tries. The results show that TXA reduces mortality in
trauma patients with or at risk of bleeding, with no
apparent increase in side effects [3]. If given within
three hours of injury, TXA reduces the risk of death
due to bleeding by about a third [4]. TXA administra-
tion has been shown to be highly cost-effective in high,
middle or low income countries [5]. On the basis of the* Correspondence: katharine.ker@lshtm.ac.uk
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results of the CRASH-2 trial, TXA has been included on
the WHO Essential Medicines List [6].
Since publication of the trial results, TXA has been
included into trauma care guidelines in many high
income countries. In March 2010, the British Army
incorporated TXA into combat care treatment protocols
[7] and in July 2011 the UK NHS ambulance service
agreed that TXA would be given to all adults and teen-
agers who suffer major injury in the UK. In 2011, the
US Army reviewed the evidence from the CRASH-2
trial and included TXA into its trauma treatment proto-
cols. However, bearing in mind that 90% of trauma
deaths are in low and middle income countries [8], the
potential of TXA to reduce premature mortality is likely
to be much greater in these settings. An estimation of
the number of deaths that could be averted through the
use of TXA for in traumatic haemorrhage would allow
better targeting of dissemination and implementation
activities. In this study we used data from the CRASH-2
trial, WHO mortality database and a systematic review
of the recent literature, to estimate the potential number
of deaths that could be averted through the early admin-
istration of TXA to bleeding trauma patients.
Methods
Estimation of effect of TXA on death due to bleeding by
geographical region
We used individual patient data from the CRASH-2 trial
to assess the extent to which the effect of TXA on
death due to bleeding varied according to geographical
region. Hospitals participating in the CRASH-2 trial
were grouped into four geographical regions: (1) Africa,
(2) Asia, (3) Europe, Australia, North America, and (4)
Central & South America. Heterogeneity in treatment
effect by geographical region was assessed by a c2 test.
We pre-specified that unless there was strong evidence
against the null hypothesis of homogeneity of effects (i.
e. p < 0.001), the overall risk ratio (RR) would be con-
sidered to be the most reliable guide to the approximate
RRs in all regions.
Estimation of number of in-hospital trauma deaths due to
bleeding per year
The number of in-hospital trauma deaths that are due
to bleeding and thus potentially avoidable through the
early administration of TXA was estimated in three
steps.
First, we obtained estimates of the number of trauma
deaths (NT) by country. Since the risk of death due to
bleeding may vary according to type of injury (i.e. blunt
or penetrating) [9], we classified deaths as being a result
of blunt trauma (NBT) or penetrating trauma (NPT). Sec-
ond, we obtained data on the proportion of trauma
deaths that occur in hospital (PH). The numbers of in-
hospital blunt trauma deaths (NH, BT) and in-hospital
penetrating trauma deaths (NH, PT) were then estimated
according to the following equations:
NH,BT = NBT × PH
NH,PT = NPT × PH
Third, we obtained data on proportion of in-hospital
blunt trauma deaths caused by bleeding (PH, BT, BL) and
the proportion of in-hospital penetrating trauma deaths
caused by bleeding (PH, PT, BL). Using these estimates we
derived the number of in-hospital trauma deaths caused
by bleeding (NH, T, BL) as follows;
NH,T,BL = (NH,BT × PH,BT,BL) + (NH,PT × PH,PT,BL)
The number of premature deaths potentially averted
by TXA was then estimated by applying the relative risk
reduction from the CRASH-2 trial to the number of in-
hospital deaths due to bleeding as follows:
Premature deaths averted = NH,T,BL × (1− RR)
Data sources
Data from the WHO, the CRASH-2 trial and a systema-
tic review of literature published since 2004 were used
to parameterise the equations. The number of trauma
deaths for each country, were obtained from the WHO
for the year 2008, the most recent year for which data
were available. Blunt trauma deaths were estimated by
adding the number of deaths from road traffic crashes,
falls and other unintentional injuries. Penetrating trauma
deaths were estimated by adding the number of deaths
from violence and war. Deaths from drowning, poison-
ing, self-inflicted injuries or burns were not included as
these injuries are not usually associated with life-threa-
tening bleeding. Estimates of the proportion of trauma
deaths that are in-hospital and the proportion caused by
bleeding were based on data from the CRASH-2 trial
and from studies identified through a systematic review.
Systematic review methods
We searched for studies containing original data
describing the epidemiology of trauma deaths. We
searched MEDLINE, EMBASE and Cab Abstracts on 2
March 2011 using a combination of subject headings
and key words based on the following terms; injuries,
trauma, mortality, death, fatality, burden, epidemiology.
We searched the internet and checked the reference
lists of eligible articles. The searches were not restricted
by language or publication status. To improve the
applicability of the extracted data to the current patterns
in trauma death epidemiology, we limited our search to
studies published since 2004.
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Record screening, full text review and data extraction
were performed independently by two authors (KK and
JK), with any disagreements resolved through discussion.
Data were extracted on study design, setting, sample
size, the proportions of deaths occurring in hospital and
due to bleeding, using a pre-designed form. Studies that
did not provide data on any of the parameters of inter-
est were excluded.
To obtain a summary estimate for each parameter, the
study proportions were transformed according to the
Freeman Tukey variant of the arcsine square root trans-
formed proportions to correct for over-dispersion [10].
Pooled proportions were calculated as the back-transfor-
mation of the weighted mean of the transformed pro-
portions using the random effects model [11].
Data analysis
For each country, the number of in-hospital trauma
deaths due to bleeding was calculated by applying the
corresponding estimated proportions to the mortality
data, as described above. For the primary analysis, the
relative risk reduction from the CRASH-2 trial was
applied to estimate the number of premature deaths
that could be averted (1) if all patients received TXA
within one hour of injury, and (2) if all patients received
TXA within three hours of injury. The numbers of
deaths averted in each country were combined to give
an overall global estimate. To identify the countries with
the greatest potential for benefit from TXA, countries
were ranked in order of the estimated number of pre-
mature deaths averted.
To investigate the impact on the results of uncertainty
in the parameter estimates used in the modelling, a
number of sensitivity analyses were conducted. First, the
analysis was repeated using the lower and upper bounds
of the 95% confidence intervals for the parameter esti-
mates to explore the effect of parameter uncertainty.
Second, we repeated the analysis using the relative risk
estimate for all-cause mortality rather than death due to
bleeding. This analysis was conducted to take account
of the possibility that some patients who do not die
from bleeding because of TXA administration would
nevertheless die of other causes such multi-organ failure
or brain injury. Third, we repeated the analyses using
the relative risk estimate for all-cause mortality with
TXA when given at any time within eight hours of
injury. Although, previously published subgroup analyses
show that early treatment is more effective it is possible
that treatment within three hours is not possible in
some settings.
For each estimate, to reflect statistical uncertainty
around the relative risks of TXA, an uncertainty range
was estimated by calculating the numbers of deaths
averted based on the 95% confidence intervals for the
relative risks. The analyses were conducted using Micro-
soft Excel and STATA 11 (TX: StataCorp LP) software.
Results
Estimation of the effect of TXA on death due to bleeding
by geographical region
Figure 1 shows the effect of TXA given within three
hours of injury on death due to bleeding by geographical
region. There was no evidence for heterogeneity in the
effect of TXA by region (c2 = 1.445; p = 0.70). The
overall RRs for the effect of TXA on death due to bleed-
ing when given within one hour (RR = 0.68; 95% CI 0.57
to 0.82) and within three hours (RR = 0.72; 95% CI 0.63
to 0.83) of injury were therefore taken as the most reli-
able guide as to the approximate RRs in all regions, and
were used to estimate the number of deaths that could
be averted with TXA.
Estimation of the annual number of in-hospital trauma
deaths due to bleeding
We identified 18 studies, described in 17 reports
[12-28], which presented data on the parameters of
interest and were included in the systematic review. Stu-
dies were conducted in 13 countries; USA, Canada, UK,
Australia, Brazil, Denmark, Norway, Mozambique, South
Africa, Italy, France, Spain and India. In addition, we
obtained data collected as part of the CRASH-2 trial,
which recruited patients from hospitals in 40 countries
throughout the world. The study selection process is
summarised in Figure 2. Data extracted from the studies
are summarised in Additional File 1.
Fourteen studies [13-15,17,19-27] involving 24,831
trauma deaths provided data on the proportion of
deaths occurring in-hospital; the pooled proportion was
44% (95% CI 33 to 56%). Five studies [3,12,16,18,28]
involving 9684 deaths presented data on the proportion
of blunt trauma deaths due to haemorrhage; the pooled
proportion was 18% (95% CI 13 to 23%). Four studies
[3,12,16,28] involving 2256 deaths presented data on the
proportion of penetrating trauma deaths due to
n/N Riskratio(95%CI)
Africa 208/3,927
Asia 196/3,688
95/1,960
Central&SouthAmerica316/3,909
Overall 815/13,484
ɍ2= 1.445;p=0.70
0.40.2 1.41.20.80.6 1
Europe,Australia&
NorthAmerica
0.68(0.52Ͳ0.90)
0.81(0.62Ͳ1.08)
0.63(0.42Ͳ0.94)
0.72(0.58Ͳ0.90)
0.72(0.63Ͳ0.83)
Figure 1 Risk ratio (95% CI) for death due to bleeding with
TXA given within three hours of injury, overall and by
geographical region.
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haemorrhage; the pooled proportion was 55% (95% CI
49 to 62%).
After applying these parameter estimates to the WHO
data, we estimate that worldwide every year approxi-
mately 400,000 trauma patients die in-hospital from
bleeding. If all of these patients receive TXA within one
hour of injury the about 128,000 (uncertainty range
[UR] ≈ 72,000 to 172,000) deaths could be averted. If all
of these patients receive TXA within three hours of
injury about 112,000 (UR ≈ 68,000 to 148,000) deaths
could be averted. The global distribution of number of
premature deaths averted by TXA when administered
within three hours of injury is shown in Figure 3.
Results for the countries where more than 1000 deaths
could be averted are shown in Table 1. The largest
numbers of deaths from haemorrhage and consequently
the largest numbers of deaths averted are in Asia. The
largest numbers of premature deaths averted are in
India (TXA ≤ 1 hr ≈ 19,000; TXA ≤ 3 hrs ≈ 16,500) and
China (TXA ≤ 1 hr ≈ 17,000; TXA ≤ 3 hrs ≈ 15,000).
When ranked by the number of premature deaths
potentially averted, nine of the top ten countries are low
or middle income, the exception being the USA where
approximately 4,000 and 3,500 deaths would be averted
by TXA given within one hour and three hours of
injury, respectively.
Sensitivity analyses
When the analyses were repeated using the values of the
lower and upper 95% CIs of the pooled parameter esti-
mates, the global number of deaths averted ranged from
approximately 76,000 to 198,000 if TXA is given within
one hour of injury and from 67,000 to 173,000 if given
with three hours of injury. When the analysis was car-
ried out using the relative risk estimate for all-cause
mortality if TXA is given within one hour (RR = 0.87;
0.78 to 0.97) and within three hours (RR = 0.87; 0.80 to
0.94) of injury, the number of premature deaths averted
was 52,000 (TXA ≤ 1 hr ≈ 12,000 to 88,000; TXA ≤ 3
hrs ≈ 24,000 to 80,000). When the analysis was repeated
using relative risk estimate for death due to bleeding
when TXA is given at any time within eight hours of
injury (RR = 0.85; 0.76 to 0.96), the number of prema-
ture deaths averted was 60,000 (UR ≈ 16,000 to 96,000).
Finally, using the relative risk estimate for all-cause
mortality when TXA is given within eight hours of
injury (RR = 0.91; 0.85 to 0.97), an estimated 36,000
(UR ≈ 12,000 to 60,000) premature deaths could be
averted.
R d id tifi d th h Additi l d id tifi decor s en e  roug 
databasesearching(n=1114)
ona recor s en e 
throughothersources(n=6)
RecordsexcludedRecordsafterduplicates
removed and screened
(n=1041) 
(n=1120)
FullͲtextarticlesassessedfor
eligibility(n=72)
(7 f ll il bl )
FullͲtextarticlesexcluded
(n = 53) u textsunava a e  
Studiesprovidingeligibledata
andincludedinpooled
analyses(n=19)
Figure 2 Flow diagram of the study selection process for
systematic review.
Figure 3 Global distribution of number of deaths averted with TXA administration within three hours of injury.
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Discussion
Based on WHO mortality data and a systematic review
of the literature we estimate that there are about
400,000 in-hospital deaths from bleeding each year
worldwide. If all hospitalised bleeding trauma patients
could be treated with TXA within an hour of injury
then up to 128,000 of these premature deaths could be
averted. If they could be treated within three hours of
injury then up to 112,000 premature deaths could
averted. Although there is considerable uncertainty in
the estimates even the most conservative suggest that
tens of thousands of deaths could be averted every
year.
We found no compelling evidence that the effect of
TXA on death due to bleeding varies by geographical
region. Our conclusion is based on a statistical test of
interaction which is considered to be the most appropri-
ate way to evaluate subgroup effects [29]. As recom-
mended by methodologists, we pre-specified that unless
there was strong evidence against the null hypothesis of
homogeneity of effects (i.e. p < 0.001), that the overall
risk ratio (RR) would be considered to be the most
reliable guide to the approximate RRs in all regions. We
found no statistical basis to reject the null hypothesis.
The data sources used to parameterise the model are
subject to a number of limitations which may have
affected our results. First, although the WHO database
provides the best available country-level mortality data,
poor coverage and coding of mortality registration sys-
tems may affect the accuracy of the number of trauma
deaths for some countries. Second, our classification of
trauma deaths into blunt or penetrating trauma based
on the cause of death categories in the WHO data was
somewhat arbitrary and would have resulted in some
misclassification. However, in the absence of accurate
country-specific data, we judged that this approach
would provide the most reliable estimates. Third, due to
the absence of country-specific data for the proportions
of deaths occurring in hospital and the proportion of
deaths caused by haemorrhage, we chose to apply aver-
age global estimates. We were therefore unable to incor-
porate between-country variations in these parameter
estimates into our analysis. Nevertheless, our estimates
were derived from a systematic review of the recent
Table 1 Estimated number of premature trauma deaths averted by TXA per year
In-hospital trauma deaths from bleeding Deaths averted TXA ≤ 1 hour Deaths averted TXA ≤ 3 hours
Worldwide 400,467 128,149 112,131
Countries with > 1000 deaths averted
India 58,801 18,816 16,464
China 54,241 17,357 15,187
Brazil 19,187 6,140 5,372
Russian Federation 16,731 5,354 4,685
Myanmar 13,193 4,222 3,694
Iraq 12,786 4,091 3,580
USA 12,489 3,996 3,497
Indonesia 11,033 3,531 3,089
DR Congo 9,373 2,999 2,624
Sri Lanka 8,979 2,873 2,514
Pakistan 8,770 2,806 2,456
Ethiopia 8,768 2,806 2,455
Nigeria 8,258 2,643 2,312
Colombia 7,348 2,352 2,058
Sudan 7,292 2,334 2,042
Bangladesh 7,210 2,307 2,019
Mexico 7,059 2,259 1,976
Philippines 6,119 1,958 1,713
Thailand 5,572 1,783 1,560
Afghanistan 4,774 1,528 1,337
Uganda 4,620 1,478 1,294
South Africa 4,245 1,359 1,189
Venezuela 4,172 1,335 1,168
Kenya 4,029 1,289 1,128
Tanzania 3,969 1,270 1,111
Iran 3,921 1,255 1,098
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literature and data from the CRASH-2 trial, and thus
represent the most accurate estimates available. We also
performed sensitivity analyses to assess the impact of
uncertainty around the parameter estimates.
Since many deaths from self-inflicted injuries are not
usually associated with life-threatening haemorrhage (e.
g. self-poisoning, hanging) we excluded this category to
avoid over-estimating the number of deaths due to
bleeding. However, this is likely to have led to the exclu-
sion of some self-inflicted deaths that were associated
with haemorrhage, in which case we may have underes-
timated the potential of TXA administration.
Our analysis was based on a number of assumptions.
We have assumed that there was no use of TXA as a
treatment for traumatic bleeding prior to publication of
the CRASH-2 trial results. It is possible that a small
proportion of the trauma deaths in our sample did
receive TXA prior to their death, which may over-esti-
mate the number of deaths averted. However, given that
any such prior use of TXA would have been minimal it
is unlikely to have greatly affected our overall estimates.
The objective of our analysis was to estimate the
potential number of deaths that could be averted assum-
ing TXA use under optimal conditions, that is, when
administered appropriately and within three hours of
injury, to all eligible bleeding trauma patients. It is
unrealistic that such conditions are consistently and
fully achieved in clinical practice. For example, the
opportunity to treat some eligible patients will be
missed and errors in the dose used or its administration
may reduce the beneficial effect of TXA.
We assumed that the results of the CRASH-2 trial could
be extrapolated to all hospitalised bleeding trauma
patients. The CRASH-2 trial used clinical criteria to
recruit a large number of patients from 274 hospitals in 40
countries, which helps the results to be generalised widely.
Whilst we acknowledge that the underlying risk of death
will vary in different settings, this does not necessarily
imply that that the relative effect will vary. Indeed, relative
effects are often remarkably homogeneous despite differ-
ences in underlying risk. This is supported by empirical
evidence from a range of trials in which the relative effects
are constant across variations in baseline risk [30].
Furthermore, there is no reason to suppose that the
mechanism of action of TXA would vary in different
populations. However, we acknowledge that the appropri-
ateness of such extrapolation is a matter of judgement.
A further assumption is that all trauma patients
reached hospital in time to receive early treatment with
TXA; that is either within one hour or within three
hours of injury. Such a time frame is unlikely to be rea-
listic in many settings where long distances and other
logistical difficulties may delay arrival at hospital. For
this reason we performed sensitivity analyses based on
the relative effect of TXA from a more conservative esti-
mate of time-to-treatment of within eight hours of
injury, the results of which still suggest that up to
60,000 deaths could be averted. Besides, there is reason
to predict that time between injury and treatment would
be shorter in clinical practice than in the CRASH-2 trial
as delays caused by consent procedures would be
avoided [31].
In applying the RR of death due to bleeding in our
primary analysis we assumed that all deaths in this
group would be avoided. However, it is possible that
whilst TXA may prevent death due to bleeding, some
patients would die from other causes instead. If this is
the case, then our primary analysis would over-estimate
the number of death averted. To address this we per-
formed a sensitivity analysis in which the effect of TXA
on all-cause mortality was used. Even using this smaller
relative reduction, up to 50,000 deaths could be averted.
We restricted our analysis to the potential benefit of
in-hospital use of TXA. However, our parameter esti-
mate of the proportion of in-hospital trauma deaths
indicates that most trauma deaths occur before arrival
at hospital. TXA is a practicable treatment suitable for
use in a range of health-care settings, including pre-hos-
pital. If TXA was used in the pre-hospital setting then
many more premature deaths might be averted.
Conclusions
Our analysis shows the potential of TXA to reduce
trauma deaths worldwide. Realisation of this potential is
likely to require further efforts in dissemination and
implementation, particularly in low and middle income
settings.
Additional material
Additional file 1: Summary of data extracted from studies included
in systematic review.
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